国产手术机器人引领者，规模化出海启程 精锋医疗-B(2675) 精锋医疗首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 江珅(分析师) | 021-23185638 | jiangshen@gtht.com | S0880525090001 | | | | 赵峻峰(分析师) | 0755-23976629 | zhaojunfeng@gtht.com | S0880519080017 | [当前价格 Table_CurPrice] (港元)： | 58.80 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | | 本报告导读： 公司是国内手术机器人引领者，通过持续技术革新推动外科手术进步，全球临床手 术量快速爬升，伴随国内销量增长以及海外市场的商业化，公司收入获得快速增长。 [Table_PicQuote] 52周股价走势图 投资要点： 风险提示。临床 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Group 1: IPO Highlights - Beijing Zhiyu Huazhang Technology Co., Ltd. (Zhiyu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code "2513," becoming the "first global large model stock" [2] - Zhiyu plans to issue 37,419,500 H-shares, with a public offering in Hong Kong receiving 1,159.46 times subscription and international offering receiving 15.28 times subscription, raising over 4.3 billion HKD at an issue price of 116.2 HKD per share [2] - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, under the stock code "9903," issuing 25,431,800 shares with a public offering subscription of 414.24 times and international offering of 10.68 times [5] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, under the stock code "0100," becoming the largest AI large model company by IPO scale in history [7] - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, under the stock code "2675," issuing 27,722,200 H-shares with a public offering subscription of 1,091.94 times and international offering of 25.18 times [9] Group 2: Company Performance and Growth - Zhiyu has achieved a revenue growth from 0.57 million CNY in 2022 to 3.12 million CNY in 2024, with a compound annual growth rate (CAGR) of 130% [3] - Tianshu's revenue increased from 1.89 billion CNY in 2022 to 5.40 billion CNY in 2024, with a CAGR of 68.8% [6] - MiniMax's revenue grew from 3.5 million USD in 2023 to 30.5 million USD in 2024, representing a year-on-year increase of 782.2% [7] - Jingfeng's revenue for the first half of 2025 reached approximately 149 million CNY, a nearly 400% year-on-year increase [10] Group 3: Market Position and Future Outlook - Zhiyu is recognized as the largest independent large model vendor in China, with significant market advantages in the enterprise sector [4] - Tianshu's products have been deployed in over 900 instances across key sectors, indicating a strong market presence [6] - MiniMax has established a user base of over 2.12 million individuals and 130,000 enterprise clients across more than 200 countries [7] - Jingfeng's robotic surgical systems have been used in over 12,000 surgeries, indicating a growing integration into standard surgical practices [9]

Group 1: IPO Dynamics - Beijing Zhipu Huazhang Technology Co., Ltd. (Zhipu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, with the stock code "2513," becoming the "first global large model stock" [3] - Zhipu plans to issue 37,419,500 H-shares, with a subscription rate of 1,159.46 times for public offerings in Hong Kong and 15.28 times for international offerings, raising over HKD 4.3 billion at an issue price of HKD 116.2 per share [3] - Zhipu's revenue from 2022 to 2024 is projected to grow from CNY 0.57 billion to CNY 3.12 billion, with a compound annual growth rate (CAGR) of 130% [4] Group 2: Market Position and Growth - The domestic large language model market is expected to grow 20 times in the next six years, with enterprise demand leading the way, providing Zhipu with a competitive advantage [5] - Zhipu's revenue is expected to exceed USD 100 million in 2025, with projections of approximately CNY 1.6 billion and CNY 2.7 billion for 2026 and 2027, respectively [5] Group 3: Other Companies' IPOs - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, with a total issuance of 25,431,800 shares and a subscription rate of 414.24 times for public offerings in Hong Kong [7] - Tianshu's revenue grew from CNY 1.89 billion in 2022 to CNY 5.40 billion in 2024, with a CAGR of 68.8% [9] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, with a total issuance of 29,197,600 shares, achieving a subscription rate of 1,837.17 times for public offerings in Hong Kong [10] - MiniMax's revenue is projected to grow from USD 3.5 million in 2023 to USD 30.5 million in 2024, with a year-on-year increase of 782.2% [11] Group 4: Financial Performance - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, with a revenue of approximately CNY 1.49 billion in the first half of 2025, representing a nearly 400% year-on-year growth [14] - Hunan Mingming Hen Mang Commercial Chain Co., Ltd. (Mingming) achieved a retail sales volume of CNY 661 billion in the first three quarters of 2025, a year-on-year increase of 74.5% [17] - Hunan Sangnisendi Group Co., Ltd. (Sangnisendi) reported revenues of CNY 1.07 billion and CNY 2.45 billion for 2023 and 2024, respectively, with a year-on-year growth of 129.5% [24] Group 5: Industry Insights - The AI and semiconductor sectors are experiencing rapid growth, with companies like Zhipu and Tianshu leading innovations in large models and computing power [4][9] - The food and beverage retail sector is also expanding, with companies like Mingming and COMMUNE establishing significant market positions [17][21] - The medical technology field is advancing with companies like Jingfeng and DeShi Biotech focusing on robotic surgery and AI in medical imaging [14][35]

Core Insights - The article highlights the emergence of Shenzhen-based Jingfeng Medical as a key player in the global surgical robot market, leveraging over 600 patents to reshape the competitive landscape dominated by foreign brands [1][2]. Company Overview - Jingfeng Medical, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with a product matrix that includes multi-port and single-port laparoscopic surgical robots, as well as natural orifice surgical robots [2]. - The company is the first in China and the second globally to obtain regulatory approval for all three types of surgical robots, positioning its technology among the world's top tier [2]. Market Trends - The penetration rate of robotic-assisted laparoscopic surgery in China is currently low at 0.7% in 2024, with expectations to rise to 3.0% by 2033, compared to 21.9% in the U.S. in 2024, indicating significant growth potential for domestic companies like Jingfeng Medical [3]. Commercialization and Financial Performance - Jingfeng Medical began commercializing its multi-port laparoscopic surgical robot in December 2022, achieving a leading position in the domestic market with 20 units sold in 2024 [4]. - The company reported revenues of 48.04 million yuan in 2023, projected to increase to 160 million yuan in 2024, with a 400% year-on-year growth in the first half of 2025 [4][5]. - The revenue structure shows that 92.9% comes from surgical robot sales, with significant contributions from overseas markets, indicating successful global expansion [5]. Investment and Funding - Jingfeng Medical has raised over 2 billion yuan through six rounds of financing, attracting investments from notable institutions such as Sequoia China and Temasek [6]. - The recent IPO attracted a strong base of cornerstone investors, reflecting high market confidence in the company's technological capabilities and growth potential [6]. Competitive Landscape - The company has established a formidable competitive barrier with its complete product matrix of multi-port, single-port, and natural orifice surgical robots, being the only company in China and one of two globally to have all these products approved [8]. - The potential for high returns is emphasized, with expectations of continued growth driven by increased penetration of robotic-assisted surgeries and expansion into international markets [8].

Group 1 - The company, 精锋医疗-B (02675), plans to conduct an IPO from December 30, 2025, to January 5, 2026, issuing 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise nearly HKD 1.2 billion [1] - The company is an advanced surgical robotics firm in the medical device industry, focusing on the design, development, and manufacturing of surgical robots, with products in various stages of research and development [1][2] - The company has received significant interest in its IPO, with a reported margin loan of HKD 478.7 billion and an oversubscription rate of 398 times for the public offering [1] Group 2 - The product portfolio includes two core self-developed products: the 精锋多孔腔镜手术机器人 (multi-port laparoscopic surgical robot) and the 精锋单孔腔镜手术机器人 (single-port laparoscopic surgical robot), along with a non-core product, the 精锋支气管镜机器人 (bronchoscopic robot) [2] - The company has established cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for a total of USD 75 million worth of shares under certain conditions [2] - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations planned for R&D (42%), commercialization (20%), capacity expansion (10%), other products (8%), strategic acquisitions (10%), and working capital (10%) [3]

Group 1 - The company, Jingfeng Medical-B (02675), plans to conduct a global offering of 27.72 million H-shares from December 30, 2025, to January 5, 2026, with a share price of HKD 43.24 per share [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the multi-port and single-port laparoscopic surgical robots [1] - The company has reported a significant increase in revenue, from RMB 48 million for the year ending December 31, 2023, to RMB 160 million for the year ending December 31, 2024 [2] Group 2 - The company has incurred operating losses during the reporting periods, with net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the respective periods due to R&D expenses [2] - The company has entered cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for shares totaling USD 75 million under certain conditions [3] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations for R&D, commercialization, capacity expansion, and potential strategic acquisitions [4]

Group 1: Market Overview - The Hang Seng Index (HSI) has shown a positive trend, closing at 25,801 points, up 111 points or 0.4%, marking its fourth consecutive day of gains [3] - The market experienced a high opening, reaching 25,859 points before facing resistance, and later fluctuated around the 20-day moving average [3] - The total market turnover was approximately HKD 169.77 billion, with a net inflow of HKD 3.125 billion from northbound trading [3] Group 2: Macro & Industry Dynamics - The Hong Kong government plans to focus on developing the gold market in 2025, aiming to establish an international gold trading center and enhance cooperation with Shanghai and Shenzhen [6][7] - The Hong Kong Stock Exchange is currently processing over 300 listing applications, indicating sustained market momentum, with expectations for continued interest from international investors [7] - The Mandatory Provident Fund (MPF) is projected to achieve a return rate of 15.35% for the year 2025, which would be the sixth-best annual performance in its 25-year history, translating to an estimated investment income of HKD 200.9 billion [8] Group 3: Company News - Country Garden (碧桂园) announced a share placement at HKD 0.4 per share, representing a discount of approximately 12.09% from the previous closing price, which will increase its issued share capital by about 0.48% [10] - Precision medical technology company, Jingfeng Medical Technology, has passed the listing hearing with plans to list on the Hong Kong main board, focusing on surgical robots [11] - GeneTech (吉因加科技) has submitted a listing application to the Hong Kong Stock Exchange, aiming to leverage AI in precision medicine and address unmet medical needs in China [12]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) has passed the listing hearing on the Hong Kong Stock Exchange, with Morgan Stanley and GF Securities as joint sponsors [1] Company Overview - Precision Medical is an advanced surgical robotics company in the medical device industry, focused on the design, development, and manufacturing of surgical robots. The company has three products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for minimally invasive procedures [3] Product Portfolio - The product lineup includes two core self-developed products: the Precision Multi-Port Laparoscopic Surgical Robot and the Precision Single-Port Laparoscopic Surgical Robot. Additionally, the company has the Precision Bronchoscopy Robot, which is not a core product. The Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries across urology, gynecology, general surgery, and thoracic surgery, while the Single-Port Laparoscopic Surgical Robot is used for surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3] Market and Regulatory Achievements - Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots. The company received its first registration approvals from the National Medical Products Administration for these products in December 2022, November 2023, and January 2025, respectively [4] Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 160 million, respectively. The company incurred losses of approximately RMB 213 million and RMB 219 million for the same periods. The financial data indicates a significant investment in research and development, with R&D expenses of RMB 171.23 million and RMB 226.25 million for the respective years [4][7]